Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity.

Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity.

Imatinib mesylate (Gleevec) inhibits Abl1, c-Kit, and related protein tyrosine kinases (PTKs) and serves as a therapeutic for chronic myelogenous leukemia and gastrointestinal stromal tumors. Imatinib also has efficacy against various pathogens, including pathogenic mycobacteria, where it decreases...

Full description

Bibliographic Details
Main Authors: Ruth J Napier, Brian A Norris, Alyson Swimm, Cynthia R Giver, Wayne A C Harris, Julie Laval, Brooke A Napier, Gopi Patel, Ryan Crump, Zhenghong Peng, William Bornmann, Bali Pulendran, R Mark Buller, David S Weiss, Rabindra Tirouvanziam, Edmund K Waller, Daniel Kalman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-03-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC4379053?pdf=render

Internet

http://europepmc.org/articles/PMC4379053?pdf=render

Similar Items